Gland Pharma announced on Friday that Srinivas Sadu has been appointed as executive chairman and chief executive officer (CEO), effective 10 June 2024.
Srinivas Sadu, a seasoned professional with over two decades of experience, has played a crucial role in Gland’s journey. Appointed MD and CEO on 25 April 2019, he has been instrumental in the company’s growth and success.
His career with the company began in 2000, and he steadily rose through the ranks to become chief operating officer in 2011.
Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
It offers a wide range of injectables, such as vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
The company also pioneered Heparin technology in India.
Also Watch: How to Develop Emotional Intelligence with Daily Practical Tips, Click Here
The pharma company reported a consolidated net profit of Rs 192.42 crore in Q4 FY24, significantly higher than the Rs 78.68 crore posted in Q4 FY23.
Revenue from operations surged 95.85% to Rs 1,537.5 crore during the quarter, compared to Rs 785.01 crore recorded in Q4 FY23.
Note: We are also on WhatsApp, LinkedIn, Google News, and YouTube, to get the latest news updates, Subscribe to our Channels. WhatsApp– Click Here, Google News– Click Here, YouTube – Click Here, and LinkedIn– Click Here.
